How GCP updates make way for an RBQM revolution

The tides are turning for clinical trial monitoring. The recent publication of ICH E6(R3) marks a pivotal shift in how sponsors and CROs approach quality management. Rather than prescribing rigid processes, the guidance encourages innovation, adaptability, and a more strategic mindset. It opens the door for smarter, more integrated approaches to trial oversight, with risk-based quality management (RBQM) at the centre.

RBQM isn’t a one-size-fits-all checklist, it’s a dynamic, risk-proportionate framework for centralised, holistic trial oversight. When implemented early, RBQM enhances protocol design, clarifies endpoints and streamlines trial execution. In this blog, we explore how RBQM can drive value beyond compliance and help sponsors and CROs deliver more agile, efficient, participant-focused clinical studies.

Why ICH GCP E6(R3) matters now

The clinical trial landscape is more complex than ever. Global studies, decentralised models and evolving endpoints demand a more adaptive approach to quality and safety as risk levels vary widely between types and models of trials. The updates to ICH GCP E6(R3) reflect a regulatory-level consideration of this variation and represents the most significant update to the GCP guidelines since their original publication over 27 years ago. The R2 version in 2016 was the first to reference more risk-based approaches and addressed some of technology advancements to keep up with modern clinical practice. However, the R3 revision is more transformative.

ICH GCP E6 (R3) places greater emphasis on:

identifying critical-to-quality (CtQ) factors early
applying risk-proportionate, flexible quality management
enabling continuous risk assessment and oversight

This shift sets a global regulatory precedent and gives sponsors and CROs more freedom to influence study design from the outset. It encourages collaboration across functions and supports a more strategic approach to trial planning.

Integrating QbD and RBQM early in study design

RBQM has the potential to shape protocol design. Protocol design has a broad range of impact across the clinical trial, meaning that even small details can have significant downstream impacts.

The release of ICH E6(R3), aligned with Quality by Design (QbD) principles, reinforces a critical shift in clinical development: the need to identify Critical to Quality (CtQ) factors and risks to participant safety and data reliability early in the trial lifecycle.

When risk assessments are embedded early, at the protocol feasibility and design stage, they bring cross-functional insights that help pre-empt common challenges—such as site feasibility issues, ambiguous endpoints, participant burden and enrolment hurdles. This proactive approach not only enhances trial design but also mitigates the risk of costly protocol amendments, which continue to be a major source of delays and financial strain across the industry.

RBQM plays a pivotal role in this transformation. This focus on risk-based approaches at earlier stages identifies critical data and processes that directly impact trial outcomes and enable:

Simplification of overly complex protocols
Better alignment between endpoints and operational feasibility
Elimination of non-essential assessments that add burden without value

CROs with mature RBQM frameworks can deliver significant value at the protocol development phase. A team of cross-functional operational leads can evaluate protocols through the lens of feasibility and strategic alignment with insight into downstream execution efficiency. This early input supports faster study startup, mitigates the risk of mid-study disruptions, and reduces operational burden on sites.

Intelligent risk monitoring strategies

A proportionate, risk-based approach to monitoring is now a strategic necessity. Under the RBQM framework, monitoring evolves from static plans to dynamic strategies tailored to the protocol complexity and Critical to Quality (CtQ) factors—enabling smarter, more efficient oversight.

In place of 100% individual source data review (SDR) and source data verification (SDV), RBQM enables a targeted approach guided by early risk assessments and real-time central monitoring. Targeted SDR and SDV provides strategic overview of the risk landscape to then focus CRA efforts where oversight is most needed.

Regular quality and risk review meetings led by cross-functional teams foster shared learning, alignment and timely action. Integrated platforms and advanced data visualisation tools help detect emerging risks, clarify protocol issues and trigger early interventions where appropriate.

This approach to more holistic, tech-enabled monitoring facilitates a shift from reactive to proactive quality management for sponsors and CROs. More than just a compliance tool, intelligent risk monitoring enhances operational efficiency, optimises resource use and supports the delivery of agile, high-quality, participant-centric trials.

Future opportunities for RBQM

ICH E6(R3) acknowledges the role of technological advancement in clinical trials and in driving RBQM through scalable digital tools. As more data is captured outside traditional EDC through tools like eDiaries, eCOAs, ePROs and wearables, the traditional monitoring methods are no longer feasible or sufficient. Remote and centralised monitoring have become essential to ensure data quality and timely risk detection. Platforms like Clinical Data Studio unify disparate data streams, enabling a shared monitoring environment for real-time signal detection and faster, risk-informed decision-making.

AI tools, supported by human oversight, can help identify trends and risks earlier. This enables adaptive monitoring without increasing burden. As technology continues to evolve, the adoption of more intelligent digital platforms and predictive analytics will help visualise data risks and automate sampling decisions for targeted monitoring.

A shift in mindset

Regulatory and industry approaches to data monitoring are shifting. The final ICH GCP E6(R3) guidance encourages sponsors and CROs to adopt flexible, right-sized, risk proportionate approaches that are tailored to the needs of each trial. A bespoke RBQM strategy optimises monitoring and creates a ripple effect across the trial. It enhances protocol design, improves resource allocation, reduces operational burden by focusing on what matters most—protecting participant safety and data reliability.

To succeed, organisations need partners who understand change management and can support this shift in mindset. Starting RBQM early with cross-functional collaboration and the right technology to support informed decisions will drive overall trial success.

Connect with us to learn how tailored RBQM strategies can deliver optimised trials, higher visibility and more control from day one.

Risk-based transformation

Why ICH GCP E6(R3) matters now

Integrating QbD and RBQM early in study design

Intelligent risk monitoring strategies

Future opportunities for RBQM

A shift in mindset

In this section

Connect with us